Unlock stock picks and a broker-level newsfeed that powers Wall Street.
1.3750
-0.0850
(-5.82%)
At close: April 4 at 6:04:48 PM GMT+3
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Antti Vuolanto D.Sc. (Tech) | Chief Executive Officer | -- | -- | 1975 |
| Ms. Tone Kvale | Chief Financial Officer | -- | -- | 1969 |
| Dr. Henri J. Huttunen Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Mr. Jani Koskinen | Head of CMC | -- | -- | -- |
Herantis Pharma Oyj
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 11
Description
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.
Corporate Governance
Herantis Pharma Oyj’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
March 6, 2025 at 6:00 AM UTC
Herantis Pharma Oyj Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
NANOFH.HE Nanoform Finland Oyj
1.0900
-7.16%
78D.F Alzinova AB (publ)
0.1886
+21.83%
FARON.HE Faron Pharmaceuticals Oy
2.4300
-2.61%
FARN.L Faron Pharmaceuticals Oy
215.00
+2.38%
VLA.PA Valneva SE
2.6140
-17.59%
STRO Sutro Biopharma, Inc.
0.5421
-8.51%
CYBN Cybin Inc.
5.69
-4.53%
VERV Verve Therapeutics, Inc.
3.6200
-5.85%
MNMD Mind Medicine (MindMed) Inc.
5.43
-2.16%
ATAI Atai Life Sciences N.V.
1.3100
-0.38%